α2-Antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism

Circulation

Volumn 95, Issue 7, 1997, Pages 1886-1891

  Butte, Anjum N ^b,c   Houng, Aiilyan K ^a   Jang, Ik Kyung ^b,c   Reed, Guy L ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

embolism; fibrinolysis; plasminogen activators; 2 antiplasmin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; DIGOXIN ANTIBODY; FIBRINOGEN; HEPARIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CONTINUOUS INFUSION; CONTROLLED STUDY; FERRET; HEPARINIZATION; HYBRIDOMA; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THROMBOEMBOLISM;

EID: 0030899525     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1886     Document Type: Article

References (37)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
2. Lilienfeld DE, Chan E, Ehland J. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest. 1990;98: 1067-1072.
3. Giuntini C, Di Riccio G, Marini C, Melillo E, Palla A. Epidemiology. Chest. 1995;107:3S-9S.
4. Sutton GC, Hall RJC, Kerr IH. Clinical course and late prognosis of treated subacute massive, acute minor, and chronic thromboembolism. Br Heart J. 1977;39:1135-1192.
5. Salzman EW, Hirsh J. The epidemiology, pathogenesis and natural history of venous thrombosis. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: Lippincott; 1994: 1275-1296.
6. Goldhaber S. Contemporary pulmonary embolism thrombolysis. Chest. 1995;107:45S-51S.
7. Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J, Kim DS, Kessler CM, Dawley DL, Sharma GVKR, Sasahara A, Grossbard EB, Braunwald E. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet. 1986; 2:886-889.
8. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation. 1973;47:1-108.
9. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, Sobel M, Wheeler HB, Plante D, Kim H, Hopkins A, Tufte M, Stump D, Braunwald E. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med. 1990;88:235-240.
10. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, Mogtader A, McDonough TJ, Braunwald E. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993; 341:507-511.
11. Prewitt RM. Principles of thrombolysis in pulmonary embolism. Chest. 1991;99:157S-164S.
12. Collen D. Identification and some properties of a new fast reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69: 209-216.
13. 2-plasmin inhibitor from human plasma. J Biol Chem. 1976;251:5956-5965.
14. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976;159:545-553.
15. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and hemostasis. J Clin Invest. 1982;69:536-542.
16. 2-antiplasmin and plasminogen inhibitor-1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost. 1993;70:301-306.
17. Francis CW, Marder VJ. Rapid formation of large molecular weight α-polymers in cross-linked fibrin induced by high factor XIII concentrations: role of platelet factor XIII. J Clin Invest. 1987;80: 1459-1465.
18. Jansen JWCM, Haverkate F, Koopman J, Niewenhuis HK, Kluft C, Boschman TAC. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost. 1987;57:171-175.
19. 2-antiplasmin-fibrin crosslinking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis. Trans Assoc Am Physicians. 1991;104:21-28.
20. Stringer HA, Pannekoek H. The significance of fibrin binding by plasminogen activator-1 for mechanism of tissue-type plasminogen activator-mediated fibrinolysis. J Biol Chem. 1995;270: 11205-11208.
21. Carmeliet P, Stassen J, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice, II: effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756-2760.
22. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994;89:2715-2721.
23. Marsh JJ, Konopka RS, Lang IM, Wang HY, Pedersen C, Chiles P, Reilly CF, Moser KM. Suppression of lysis in a canine model of pulmonary embolism. Circulation. 1994;90:3091-3097.
24. 2-plasmin inhibitor deficiency. Blood. 1983;62:1118-1122.
25. 2-antiplasmin. Blood. 1982;59: 1246-1251.
26. 2-antiplasmin. Trans Assoc Am Physicians. 1988;101:250-256.
27. 2-antiplasmin. Proc Natl Acad Sci U S A. 1990;87: 1114-1118.
28. Galfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981;73:3-46.
29. Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol. 1989;169:3-11.
30. Rampling MW, Gaffney PJ. The sulphite precipitation method for fibrinogen measurement: its use on small samples in the presence of fibrinogen degradation products. Clin Chim Acta. 1976;67:43-52.
31. Werier J, Ducas J, Gu S, Chan SM, Prewitt RM. Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. Chest. 1991;100:464-469.
32. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
33. Reed GL, Lukacova D. Generation and mechanism of action of a potent inhibitor of factor XIII function. Thromb Haemost. 1995;74: 680-685.
34. Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood. 1990;75: 1455-1459.
35. Passamani E, Hodges M, Herman M, Grose R, Chaitman B, Rogers W, Forman S, Terrin M, Knatterud G, Robertson T, Braunwald E. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Pilot Study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1987;10:51B-64B.
36. Onundarson PT, Francis CW, Marder VJ. Depletion of plasminogen in vitro during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med. 1992;120:120-128.
37. Mudgett-Hunter M, Anderson W, Haber E, Margolies MN. Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies. Mol Immunol. 1985;22:477-488.